Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASCO Annual Meeting Coverage

Set Alert for ASCO Coverage

ASCO Review: Progress Is Where You Find It

In another year roundly critiqued as being “quiet” on major clinical advances, the American Society of Clinical Oncology annual meeting allowed other areas to shine. 
ASCO Clinical Trials Cancer

With New Leadership, Roche Goes Back To Basics At ASCO

In a time of internal transition, Roche emphasized its deep roots and broad pipeline at its annual event alongside the American Society for Clinical Oncology meeting.
ASCO Business Strategies Cancer

Latest From ASCO

Weak SOPHIA OS Signal Dampens Enthusiasm For MacroGenics’ Margetuximab

Whether MacroGenics’ margetuximab can produce an overall survival benefit from the SOPHIA study could be key to its commercial fortunes, say analysts. The company remains optimistic.

Clinical Trials ASCO

Roche Outlines Use Of Real-World Evidence In Entrectinib NDA

Roche used its Flatiron Health oncology EHR database to generate an external control arm for pivotal single-arm data supporting the personalized medicine candidate, which has an 18 August user fee goal.
ASCO Innovation

BeiGene, Hengrui Among China Firms Flexing New Oncology Muscle At ASCO

In its bid to facilitate novel treatments for some of its most prevalent cancers, China is also poised to make a dent in the global oncology market through domestically originated agents, with the number of PD-1 and CAR-T therapies under clinical development already surpassing that in the US.

ASCO China

BIO 2019 Notebook: M&A Soars, Lartruvo Lookback, BIO Vs. ASCO

News and views from day four of the BIO International Convention: emerging company M&A deals nearly double in 2018; former FDA official Amy McKee said "everything worked right" with accelerated approval and removal of Lilly's Lartruvo; and the ASCO effect on the 3-6 June BIO meeting.

Drug Review Review Pathway

BIO 2019 Notebook: Lartruvo Lookback, M&A Soars, BIO Vs. ASCO

News and views from day four of the BIO International Convention: Former FDA official Amy McKee said "everything worked right" with accelerated approval and removal of Lilly's Lartruvo; emerging company M&A deals nearly double in 2018; and the ASCO effect on the 3-6 June BIO meeting.

Drug Review Review Pathway

US Drug Pricing Reforms: ASCO Hears About Bargaining Chips And Baby Steps

Former long-time congressional health staffer Rodney Whitlock discusses the status of prescription drug pricing reform policies in the administration and congress at the American Society for Clinical Oncology annual meeting.

Pricing Debate Reimbursement

ASCO Review: Progress Is Where You Find It

In another year roundly critiqued as being “quiet” on major clinical advances, the American Society of Clinical Oncology annual meeting allowed other areas to shine. 

ASCO Clinical Trials

So Far, Still So Good For Seattle Genetics/Astellas’ Bladder Cancer ADC

Updated data from the Phase II EV-201 study of Seattle Genetics/Astellas Pharma’s novel ADC are strong enough to warrant accelerated approval, its investigators claim. An accelerated submission to the US FDA is due later this year.

ASCO Clinical Trials

Lartruvo Could Be A Failure Of The Drug, The Design Or The Disease

The presentation of the ANNOUNCE results, the failed confirmatory trial for Lilly’s Lartruvo, at ASCO re-opened questions about the accelerated approval and the appropriate way to study soft tissue sarcoma. 
ASCO Clinical Trials
See All
Advertisement
UsernamePublicRestriction

Register